Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Molecules ; 27(24)2022 Dec 08.
Artigo em Inglês | MEDLINE | ID: mdl-36557841

RESUMO

Advancement in nanotechnology has unleashed the therapeutic potentials of dietary polyphenols by enhancing bioavailability, improving biological half-life, and allowing site-specific drug delivery. In this review, through citation of relevant literature reports, we discuss the application of nano-pharmaceutical formulations, such as solid lipid nanoparticles, nano-emulsions, nano-crystals, nano-polymersomes, liposomes, ethosomes, phytosomes, and invasomes for dietary polyphenols. Following this, we highlight important studies concerning different combinations of nano formulations with dietary polyphenols (also known as nanophytopolyphenols). We also provide nano-formulation paradigms for enhancing the physicochemical properties of dietary polyphenols. Finally, we highlight the latest patents that were granted on nano-formulations of dietary polyphenols. Based on our review, we observe that nanosized delivery of herbal constituents, spices, and dietary supplements have the ability to improve biological processes and address issues connected with herbal treatments.


Assuntos
Sistemas de Liberação de Medicamentos , Nanopartículas , Nanopartículas/química , Polifenóis , Disponibilidade Biológica , Emulsões , Suplementos Nutricionais
2.
Mini Rev Med Chem ; 21(20): 3191-3202, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-33632095

RESUMO

Corona Virus Disease-2019 (COVID-19), caused by the SARS CoV-2 virus, has been announced as a pandemic by the World Health Organization. COVID-19 has affected people globally, infecting more than 39.8 million people and claiming up to 1.11 million lives, yet there is no effective treatment strategy to cure this disease. As vaccine development is a time-consuming process, currently, efforts are being made to develop alternative plans for the timely and effective management of this disease. Drug repurposing always fascinated researchers and can be utilized as the most acceptable alternative to develop the therapeutics for COVID-19 using the pre-approved drugs. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has shown resemblance with distinctive enzyme targets, such as 3CLpro/Mpro, RdRp, Cathepsin L, and TMPRSS2 present in SARS CoV and MERS CoV. Therefore, the drugs that have shown efficacy in these viruses can also be used for the treatment of COVID-19. This review focuses on why repurposing could provide a better alternative in COVID- 19 treatment. The similarity in the structure and progression of infection of SARS CoV and MERS viruses offers a direction and validation to evaluate the drugs approved for SARS and MERS against COVID-19. It has been indicated that multiple therapeutic options that demonstrate efficacy against SARS CoV 2 are available to mitigate the potential emergence of COVID-19 infection.


Assuntos
Antivirais , Tratamento Farmacológico da COVID-19 , Infecções por Coronavirus/tratamento farmacológico , Reposicionamento de Medicamentos , Síndrome Respiratória Aguda Grave/tratamento farmacológico , Antivirais/farmacologia , Antivirais/uso terapêutico , Humanos , Coronavírus da Síndrome Respiratória do Oriente Médio/efeitos dos fármacos , Coronavírus da Síndrome Respiratória do Oriente Médio/enzimologia , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/efeitos dos fármacos , Coronavírus Relacionado à Síndrome Respiratória Aguda Grave/enzimologia , SARS-CoV-2/efeitos dos fármacos , SARS-CoV-2/enzimologia
3.
Comb Chem High Throughput Screen ; 24(10): 1528-1543, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-32957874

RESUMO

BACKGROUND: Alzheimer's disease is an irreversible, progressive brain disorder manifested with symptoms like loss of memory (known as dementia), personality changes, loss of cognition, impaired movement, confusion, deteriorated planning and thought process. Neurodegeneration in Alzheimer's disease is the result of the deposition of protein beta-amyloid that forms plaques and another protein called tau, forming tangles that prevent the proper functioning of nerve cells in the brain. METHODS: The goal of the review was to comprehensively study the utilization of nanotechnology and the role that carbon nanotubes can play as a drug delivery system for the amelioration of Alzheimer's disease. RESULTS: Nanotechnology is one of the most researched domains of modern science. It contributes significantly to therapeutics by facilitating drug therapy to reach the target sites, which are otherwise difficult to reach with conventional drug delivery systems. Carbon nanotubes are the allotropes of carbon in which several carbon atoms bind with each other to form a cylindrical or a tube-like structure. The carbon nanotubes possess several unique qualities, which confer them with a high potential of being utilized as an efficient drug delivery system. They offer high drug loading and can readily cross the toughest biological barriers like the BBB. Carbon nanotubes also facilitate the passage of drugs to the brain via the olfactory route, which further helps in restoring normal autophagy, thus preventing the elimination of autophagic chemicals. They can carry a vast range of cargos, including drugs, antigens, genetic materials, and biological macromolecules. CONCLUSION: Carbon nanotubes are a highly promising drug delivery system for anti-Alzheimer's drugs. They have the potential of overcoming the various biological barriers like the BBB. However, more extensive research is required so as to set up a firm base for the development of advanced commercial products based on carbon nanotubes for the treatment of Alzheimer's disease.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Nanotubos de Carbono/química , Fármacos Neuroprotetores/uso terapêutico , Sistemas de Liberação de Medicamentos , Humanos , Nanotecnologia , Fármacos Neuroprotetores/química
4.
Drug Deliv ; 23(9): 3364-3373, 2016 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-27128623

RESUMO

CONTEXT: The unique physiological limitations of the eye have been assigned as reason of low bioavailability by conventional drug delivery systems. There is need of such drug carriers, which ensure improved bioavailability as well as patient compliance upon instillation into the eye. OBJECTIVE: The present investigation deals with development of solid lipid nanoparticles (SLNs) containing celecoxib (CXB) for treatment of ophthalmic inflammations. MATERIALS AND METHODS: The SLNs were formulated by melt-emulsion sonication and low temperature-solidification process and evaluated for particle size, surface morphology, physicochemical properties, percentage drug incorporation efficiency, in vitro drug release, in vitro trans-corneal permeation, in vivo efficacy in ocular inflammation, stability study and gamma scintigraphy study to assess the residence of solid lipid nanoparticles over ocular surfaces. RESULTS: The SLNs were spherical and the optimized formulation had particle size of 198.77 ± 7.5 nm, which is quite suitable for ocular applications. The maximum entrapment efficiency of 92.46 ± 0.07% was achieved for formulation SLN 20. The permeation across the cornea was also significantly better than aqueous suspension (8.21 ± 0.67 versus 4.61 ± 0.71) at p < 0.05. DISCUSSION AND CONCLUSION: The SLN formulations demonstrated improved performance of entrapped CXB while mitigating the key parameters of ocular inflammation in rabbits. The particulate formulations have exhibited prolonged retention over ocular surfaces as evident from results of gamma scintigraphy using 99mTc labeled SLNs.


Assuntos
Córnea/efeitos dos fármacos , Inibidores de Ciclo-Oxigenase 2/química , Lipídeos/química , Nanopartículas/química , Animais , Disponibilidade Biológica , Celecoxib/administração & dosagem , Celecoxib/química , Celecoxib/metabolismo , Química Farmacêutica/métodos , Inibidores de Ciclo-Oxigenase 2/administração & dosagem , Inibidores de Ciclo-Oxigenase 2/metabolismo , Portadores de Fármacos/química , Sistemas de Liberação de Medicamentos/métodos , Estabilidade de Medicamentos , Emulsões/administração & dosagem , Emulsões/química , Emulsões/metabolismo , Lipídeos/administração & dosagem , Nanopartículas/administração & dosagem , Tamanho da Partícula , Permeabilidade , Coelhos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA